000 03378cam a2200349 a 4500
003 EG-GiCUC
005 20250223032041.0
008 180910s2018 ua dh f m 000 0 eng d
040 _aEG-GiCUC
_beng
_cEG-GiCUC
041 0 _aeng
049 _aDeposite
097 _aPh.D
099 _aCai01.11.07.Ph.D.2018.Di.M
100 0 _aDiana Nagy Garas Masoud
245 1 0 _aMicroRNAs as candidate biomarkers in systemic lupus erythematosus patients /
_cDiana Nagy Garas Masoud ; Supervised Taghrid Mohamed Gaafar , Noha Mohamed Hosni Shaheen , Hala Ahmed Raafat
246 1 5 _aأحماض الريبونيوكلييك الدقيقة كمؤشرات حيوية في مرضى الذئبة الحمراء
260 _aCairo :
_bDiana Nagy Garas Masoud ,
_c2018
300 _a199 P. :
_bcharts , facsimiles ;
_c25cm
502 _aThesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Clinical and Chemical Pathology
520 _aIntroduction: Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease that can affect the major»ity of organs and tissues.The clinical presentations of SLE can range from mild to severe and the course is unpredictable, with periods of remission and flares. Lupus nephritis is a severe consequence of SLE and an important driver of morbidity and mortality in SLEMicroRNAs (miRNAs) are a class of small (~22nucleotides) noncoding RNAs that modulate gene expression and regulate various cellular processes and are critically involved in many physiologic and pathologic processes in health and disease including immune system disease. Aim of work The aim of the study is to identify the use of microRNA-126 and microRNA-146a as candidate diagnostic and prognostic biomarkers and their correlation with disease activity in SLE patients Subjects and methods Our study included 74 SLE patients (66 females and 8 males) with ages ranging from 13 years to 57 years. Patients with SLE fulfilled the American College of Rheumatology classification criteria for SLE. Besides, our study included 40 age and sex matched healthy controls, for comparison. Determination of plasma levels of miR-146a and miR-126 were done using taqman quantitative Real time-PCR using RNU6B as internal controls.Measurement of serum interferon alpha (IFN-Ü) by ELISA technique was performed from SLE patients and healthy controls.Data was correlated with disease activity and hence evaluation of their prognosis. Results: The median value of fold change of plasma miR-146a levels showed a significant statistical decrease in SLE and lupus nephritis patients compared to the healthy control group and there was also a decrease in plasma levels of miR-146a in active SLE patients versus the inactive group and healthy control group. However, there was no statistical significant difference in plasma miR-126 levels and serum IFN-Ü in SLE and lupus nephritis patients compared to the healthy control group
530 _aIssued also as CD
653 4 _aLupus nephritis
653 4 _aMiR-146a
653 4 _aSystemic lupus erythematosus (SLE)
700 0 _aHala Ahmed Raafat ,
_eSupervisor
700 0 _aNoha Mohamed Hosni Shaheen ,
_eSupervisor
700 0 _aTaghrid Mohamed Gaafar ,
_eSupervisor
856 _uhttp://172.23.153.220/th.pdf
905 _aNazla
_eRevisor
905 _aShimaa
_eCataloger
942 _2ddc
_cTH
999 _c67397
_d67397